All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
51st Annual Meeting of the EBMT 2025 congress coverage
By Ella Dixon
Bookmark this article
Stay up to date with the latest developments in myeloproliferative neoplasms with our live social media coverage from the 51st Annual Meeting of the EBMT, March 30 – April 2, Florence, IT.
CONGRESS | #EBMT25 | POSTER
— MPN_Hub (@MPN_Hub) April 3, 2025
Andreas Reiter @UniHeidelberg shares findings from a retrospective study which assessed the efficacy of avapritinib in adults with advanced systemic mastocytosis (n = 38 treated with avapritinib, n = 58 treated with midostaurin).
Findings support the… pic.twitter.com/CCvsI8CjI4
CONGRESS | #EBMT25 | PRESENTATION
— MPN_Hub (@MPN_Hub) April 2, 2025
Rachel Salit presents an expert panel consensus on remission following HCT for #myelofibrosis.
The remission definition acknowledges that MF patients have active disease at HCT (therefore must distinguish persistent vs relapsed disease) and… pic.twitter.com/un8nKTRl83
CONGRESS | #EBMT25 | PRESENTATION
— MPN_Hub (@MPN_Hub) April 2, 2025
Yves Chalandon shares outcomes of PTCy vs ATG as GvHD prophylaxis in #myelofibrosis patients transplanted with allo-HCT from unmatched donors (UD) from the EBMT registry (N = 2,607).
MF patients undergoing UD allo-HCT had a decreased incidence… pic.twitter.com/iYjbUw4cFQ
CONGRESS | #EBMT25 | PRESENTATION
— MPN_Hub (@MPN_Hub) April 2, 2025
Patrizia Chiusolo shares findings from an international cohort study designed to clarify the relative efficacy and safety of PTCy vs ATG GvHD prevention strategies in HLA-matched allo-HCT for #myelofibrosis (N = 539).
Survival rates were… pic.twitter.com/IqeChXc3kV
CONGRESS | #EBMT25 | PRESENTATION
— MPN_Hub (@MPN_Hub) April 2, 2025
Patryk Sobieralski shares findings from a study which explored the association between transplant conditioning intensity (TCI) and outcome after allo-HCT for patients with MF (N = 2,454).
A lower relapse incidence was observed with intermediate… pic.twitter.com/nJ6wylO3Gd
CONGRESS | #EBMT25 | PRESENTATION
— MPN_Hub (@MPN_Hub) April 2, 2025
Ibrahim Yakoub-Agha @AghaYakoub10634 discusses the prognostic impact of updated MPN classifications for allo-HSCT, highlighting the urgent need for unification of WHO/ICC classifications into a single system.
Follow our live feed for more… pic.twitter.com/nyL4VSlAs2
CONGRESS | #EBMT25 | PRESENTATION
— MPN_Hub (@MPN_Hub) April 2, 2025
Nico Gagelmann @NicoGagelmann explores the role of MRD in #myelofibrosis, highlighting the importance of monitoring driver mutations closely with high sensitivity, and carefully reducing immunosuppression to preemptively achieve MRD negativity.… pic.twitter.com/jvKprVqiqQ
CONGRESS | #EBMT25 | PRESENTATION
— MPN_Hub (@MPN_Hub) April 1, 2025
Mathias Schäfersküpper presents findings from a prospective cohort study exploring the role of skeletal homeostasis in patients undergoing allo-HCT for #myelofibrosis (N = 66).
The study demonstrated distinct changes to the bone marrow and bone… pic.twitter.com/FpCuondqwG
CONGRESS | #EBMT25 @theEBMT | PRESENTATION
— MPN_Hub (@MPN_Hub) March 31, 2025
Nicola Polverelli @N_Polverelli discusses the role of allo-HCT in atypical MPN and overlap syndromes, highlighting the importance of early evaluation, dynamic monitoring, organ function assessment, binding strategies and a… pic.twitter.com/1WKq07OLEF
CONGRESS | #EBMT25 @theEBMT | PRESENTATION
— MPN_Hub (@MPN_Hub) March 31, 2025
Deepti Radia @DeeptiRadia @GSTTnhs explores key considerations in optimizing allo-HCT in advanced systemic mastocytosis, highlighting the importance of risk stratification scores, TKI treatment selection, transplant timing and a… pic.twitter.com/eX0ClS1qAB
CONGRESS | #EBMT25 @theEBMT | PRESENTATION
— MPN_Hub (@MPN_Hub) March 31, 2025
Juan Carlos Hernández-Boluda explores future strategies to optimize outcomes in allo-HCT for #myelofibrosis, highlighting the importance of patient selection and HCT timing, patient preparation, the roles of spleen size and irradiation,… pic.twitter.com/yfVQuZvpDf
CONGRESS | #EBMT25 @theEBMT | PRESENTATION
— MPN_Hub (@MPN_Hub) March 31, 2025
Donal McLornan @DonalMcLor @uclh discusses allo-HCT timing optimization for #myelofibrosis, highlighting the importance of early candidate and donor identification and individualized decisions based on prognostic scoring, risk categoty,… pic.twitter.com/qGrMH3PoiC
Your opinion matters
27 votes - 7 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox